NCT00701766已完成2 期
An Open, Randomised Clinical Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Efficacy, Safety and Pharmacokinetics of Repeated Three-week Courses of a Single Dose i.v. BI 2536 on Day 1 in Comparison to Single Doses i.v. BI 2536 on Days 1, 2 and 3 in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 11
- 主要终点
- Maximum tolerated dose Best objective response
研究概览
简要总结
The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML. Different schedules will be compared to identify the better dosing schedule for the further development programme of BI 2536. Dose escalation starting with the maximum tolerated dose previously determined in patients with advanced solid cancers will be performed to determine the maximum tolerated dose for AML patients.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients older than 60 years of age
- •Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy
- •Leukocyte count <= 25,000 /mcl (25 x 10e9/Liter)
- •Patient not eligible for intensive treatment options
- •Life expectancy >= 2 months
- •Eastern co-operative oncology group performance score of 2 or less
- •Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation
排除标准
- •Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)
- •Hypersensitivity to the trial drug or the excipients
- •Secondary malignancy requiring therapy
- •Known central nervous system involvement
- •Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver involvement
- •Bilirubin greater than 1.5 mg/dl (> 26 mcmol/l, SI unit equivalent)
- •Serum creatinine greater than 2.0 mg/dl
- •Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia
- •Psychiatric illness or social situation that would limit compliance with trial requirements
- •Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
- •Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug
- •Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant
- •Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)
- •Patient unable to comply with the protocol
结局指标
主要结局
Maximum tolerated dose Best objective response
时间窗: 3 weeks, throughout the study period
次要结局
- Event free survival, Overall survival, Remission duration, BI 2536 plasma concentrations, Incidence and intensity of adverse events graded according to CTCAE, PD, Incidence of DLT(throughout the study period)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00376623Boehringer Ingelheim96
已完成
2 期
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic CancerPancreatic NeoplasmsNCT00710710Boehringer Ingelheim89
撤回
1 期
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxLeukemia, Lymphocytic, Chronic, B-CellNCT03343678Boehringer Ingelheim
已完成
2 期
Ovarian Cancer Vaccine for Patients in RemissionEpithelial Ovarian CancerNCT01068509Prima BioMed Ltd63
招募中
1 期
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06223841SUNHO（China）BioPharmaceutical CO., Ltd.50